STOCK TITAN

Mineralys Therapeutics, Inc. - MLYS STOCK NEWS

Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company advancing targeted therapies for hypertension, chronic kidney disease, and sleep apnea. This page aggregates official news and press releases, providing investors with essential updates on the company’s progress in developing aldosterone-focused treatments.

Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. The curated content includes detailed announcements about lead candidate lorundrostat, a selective aldosterone synthase inhibitor, alongside financial disclosures and market analyses.

Key updates cover:

• Clinical Research: Phase advancements and trial outcomes
• Regulatory Progress: FDA communications and approval pathways
• Corporate Strategy: Collaborations and pipeline expansions
• Financial Updates: Earnings summaries and investment decisions

Bookmark this resource for direct access to primary-source MLYS developments. Visit regularly for objective reporting on innovations in cardiorenal therapeutics.

Rhea-AI Summary
Mineralys Therapeutics, Inc. CEO Jon Congleton will participate in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference in New York City on February 8, 2024. The company focuses on developing medicines for hypertension, chronic kidney disease, and other diseases driven by elevated aldosterone levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the appointment of Minji Kim, Ph.D. as Chief Business Officer, splitting the functions of CFO and CBO into two roles. Dr. Kim brings over two decades of experience in business development, strategic leadership, and scientific research, having worked with biotech companies in the U.S. and overseas. She has a solid track record of generating value for companies and brings extensive experience in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
management
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announces the dosing of the first subject in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company expects to release topline data from the confirmatory Launch-HTN trial in the second half of 2025 and from the ongoing Advance-HTN pivotal trial in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
Rhea-AI Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) presents new data from the Target-HTN Phase 2 trial at the American Heart Association Scientific Sessions 2023. The analysis reveals a positive feedback loop between obesity, leptin, and aldosterone, indicating potential benefits for obese patients with uncontrolled or resistant hypertension from lorundrostat treatment. Serum leptin levels and BMI are correlated, suggesting leptin as a biomarker for lorundrostat-responsive individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) announced senior management's participation in upcoming healthcare conferences in New York, London, and Miami. The company will present and engage in fireside chats, discussing its focus on developing medicines for hypertension, chronic kidney disease, and other aldosterone-driven diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.84%
Tags
conferences
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announces plans to initiate Phase 3 pivotal Launch-HTN trial of lorundrostat to treat uncontrolled or resistant hypertension in 2H 2023, with a Phase 2 Explore-CKD trial also set to start in the same period. The company reported financial results for Q3 2023 and provided corporate updates, including the addition of two new Board members and the upcoming poster presentation at AHA Scientific Sessions 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
Rhea-AI Summary
Mineralys Therapeutics presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, at the ASN Kidney Week 2023. The analysis identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure of 32 mmHg. The enhanced response was proportional to the elevation in body mass index (BMI) and may indicate an obesity-related, aldosterone-dependent hypertensive endotype.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023. The company focuses on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by abnormally elevated aldosterone. The conference call will be held on Tuesday, November 7th at 4:30 p.m. ET. A live webcast and replay of the call will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics announces upcoming poster presentations at scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none
Rhea-AI Summary
Mineralys Therapeutics announces new appointments to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
management
Mineralys Therapeutics, Inc.

Nasdaq:MLYS

MLYS Rankings

MLYS Stock Data

866.10M
61.04M
2%
87.07%
4.04%
Biotechnology
Pharmaceutical Preparations
Link
United States
RADNOR